Psychedelic Drug Developers Surge as Trump Expedites FDA Reviews
Published on: April 20, 2026, 6:31 p.m. | Source: Devdiscourse
U.S. President Donald Trump signed an order instructing the FDA to expedite reviews of psychedelic drugs, causing shares of related companies to rise. Atai Life Sciences and Compass Pathways saw significant increases. The order aims to boost research funding and streamline treatment access for conditions like PTSD.
